Sweden · Delayed Price · Currency is SEK Saniona AB Earnings Call Transcripts
Fiscal Year 2026
-
SAN2668 is advancing as a differentiated therapy for severe pediatric epilepsies, showing robust preclinical efficacy and improved tolerability. The program is well-funded through early clinical milestones, with a strategy to maximize value and address significant unmet needs in DEEs.
-
Strong cash reserves and major licensing deals enable progression of three CNS-focused preclinical programs into phase I trials by early 2025, with results expected in the second half of 2025. The strategy emphasizes selective GABA modulators for epilepsy and depression, aiming for further partnerships and a diversified pipeline.
-
Major licensing deals with Acadia and Jazz have strengthened financials and enabled a robust internal pipeline targeting CNS diseases. Multiple clinical programs are advancing, with near-term milestones expected and a strategy focused on both internal development and strategic partnerships.
-
Strong cash reserves and major partnerships support advancement of three internal CNS programs into clinical trials, with phase I readouts expected in 2027. Selective GABA modulators target high unmet needs in epilepsy and depression, aiming for rapid growth and future phase III readiness.
Fiscal Year 2025
-
Strong financials and major partnerships support a robust CNS pipeline, with multiple assets advancing toward clinical trials in epilepsy and depression. The company targets large markets and aims for broad regulatory labels, leveraging recent high-value industry deals.
-
Strategic focus is on advancing ion channel programs and Tesofensine, supported by a strong financial position from the Acadia deal. Anticipated milestones include Tesofensine approval in Mexico, expansion into new markets, and progress in research collaborations, with a commitment to financial discipline.